PMID- 15284264
OWN - NLM
STAT- MEDLINE
DCOM- 20040827
LR  - 20220317
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 22
IP  - 15
DP  - 2004 Aug 1
TI  - Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
PG  - 3126-32
AB  - PURPOSE: Uterine papillary serous carcinoma (UPSC) is an aggressive subtype of 
      endometrial cancer characterized by early metastasis, resistance to therapy, and 
      a high mortality rate. Little is known about the biology of these tumors. Smaller 
      studies suggest that Her-2/neu may be involved in the tumorigenesis of this 
      disease. The purpose of this study was to evaluate the protein expression and 
      gene amplification of Her-2/neu in UPSC and to determine its prognostic value. 
      PATIENTS AND METHODS: Tumor tissue from 68 patients with UPSC treated at The 
      University of Texas M.D. Anderson Cancer Center from 1989 to 2002 was available. 
      Her-2/neu expression was evaluated by immunohistochemistry (IHC). Overexpression 
      was defined as complete membrane staining in greater than 10% of the cells. In 
      tumors with overexpression of Her-2/neu by IHC, fluorescence in situ 
      hybridization (FISH) was performed to assess gene amplification. Clinical and 
      pathologic information was obtained from medical records. RESULTS: Twelve (18%) 
      of 68 tumors demonstrated Her-2/neu overexpression. Of these, only two showed 
      gene amplification. When evaluating all 68 patients, Her-2/neu overexpression was 
      associated with a poorer overall survival (OS; P = .008). In our multivariate Cox 
      proportional hazards models, Her-2/neu IHC overexpression, lymph node status, and 
      stage were each associated with OS (P < or = .05). CONCLUSION: Positive IHC 
      overexpression of Her-2/neu was seen in 18% of UPSCs but was rarely correlated 
      with Her-2/neu gene amplification. Overexpression of Her-2/neu was associated 
      with a worse overall prognosis. The use of trastuzumab (Herceptin; Genentech, 
      South San Francisco, CA) in women with UPSC should be further evaluated in a 
      clinical trial setting.
CI  - Copyright 2004 American Society of Clinical Onocology
FAU - Slomovitz, Brian M
AU  - Slomovitz BM
AD  - Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer 
      Center, 1515 Holcombe Blvd, Unit 440, Houston, TX 77030-4009, USA.
FAU - Broaddus, Russell R
AU  - Broaddus RR
FAU - Burke, Thomas W
AU  - Burke TW
FAU - Sneige, Nour
AU  - Sneige N
FAU - Soliman, Pamela T
AU  - Soliman PT
FAU - Wu, Weiguo
AU  - Wu W
FAU - Sun, Charlotte C
AU  - Sun CC
FAU - Munsell, Mark F
AU  - Munsell MF
FAU - Gershenson, David M
AU  - Gershenson DM
FAU - Lu, Karen H
AU  - Lu KH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cystadenocarcinoma, Papillary/*genetics/mortality
MH  - Female
MH  - *Gene Amplification
MH  - *Gene Expression
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Survival Rate
MH  - Uterine Neoplasms/*genetics/mortality
EDAT- 2004/07/31 05:00
MHDA- 2004/08/28 05:00
CRDT- 2004/07/31 05:00
PHST- 2004/07/31 05:00 [pubmed]
PHST- 2004/08/28 05:00 [medline]
PHST- 2004/07/31 05:00 [entrez]
AID - 22/15/3126 [pii]
AID - 10.1200/JCO.2004.11.154 [doi]
PST - ppublish
SO  - J Clin Oncol. 2004 Aug 1;22(15):3126-32. doi: 10.1200/JCO.2004.11.154.